{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T11:38:06Z","timestamp":1692790686699},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2012,2,8]],"date-time":"2012-02-08T00:00:00Z","timestamp":1328659200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s00228-012-1220-y","type":"journal-article","created":{"date-parts":[[2012,2,7]],"date-time":"2012-02-07T11:00:04Z","timestamp":1328612404000},"page":"1065-1072","source":"Crossref","is-referenced-by-count":1,"title":["Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: a case series from two national pharmacovigilance centres"],"prefix":"10.1007","volume":"68","author":[{"given":"Mira","family":"Harrison-Woolrych","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda","family":"H\u00e4rmark","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simran","family":"Maggo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kees","family":"van Grootheest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,2,8]]},"reference":[{"issue":"2","key":"1220_CR1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1503\/cmaj.070256","volume":"179","author":"MJ Eisenberg","year":"2008","unstructured":"Eisenberg MJ, Filion KB, Yavin D, Belisle P, Mottillo S, Joseph L et al (2008) Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. Can Med Assoc J 179(2):135\u2013144","journal-title":"Can Med Assoc J"},{"key":"1220_CR2","doi-asserted-by":"crossref","unstructured":"Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR; Varenicline Phase 3 Study Group (2006) Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. JAMA 296(1):47\u201355","DOI":"10.1001\/jama.296.1.47"},{"key":"1220_CR3","doi-asserted-by":"crossref","unstructured":"Aubin H-J, Bobak A, Britton JR, Oncken C, Billing CBJr, Gong J, Williams KE, Reeves KR (2008) Varenicline versus transdermal nicotine patch for smoking cessation: Results from a randomised open-label trial. Thorax 63(8):717\u201324","DOI":"10.1136\/thx.2007.090647"},{"key":"1220_CR4","unstructured":"Agency EM (2011) Champix: procedural steps taken and scientific information after the authorisation. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Procedural_steps_taken_and_scientific_information_after_authorisation\/human\/000699\/WC500025256.pdf . Accessed June 2011"},{"key":"1220_CR5","unstructured":"Federal Drug Administration (2009) Varenicline and bupropion: reports of suicidality associated with the use of varenicline and bupropion. FDA Drug Saf Newsl 2(1)"},{"key":"1220_CR6","unstructured":"Harrison-Woolrych M (2011) Psychiatric reactions with varenicline:interim results from intensive monitoring in New Zealand. Prescriber update 2009. Available at: http:\/\/medsafe.govt.nz\/profs\/PUarticles\/varencline . Accessed 30 February 2011"},{"key":"1220_CR7","unstructured":"Pfizer (2011) New Zealand data sheet for Champix. Available at: http:\/\/www.medsafe.govt.nz\/profs\/datasheets . Accessed June 2011"},{"key":"1220_CR8","unstructured":"Pfizer (2011) Summary of Product Characteristics for Champix. Available at: http:\/\/www.medicines.org.uk\/emc\/document.documentid=19045 . Accessed June 2011"},{"key":"1220_CR9","unstructured":"Pharmac (2010) Decision on proposals for venlafaxine, etanercept, varenicline, sunitinib and adalimumab. Available at: http:\/\/www.pharmac.govt.nz\/2010\/09\/28\/2010-09-28%20Pfizer%20Notification.pdf . Accessed June 2011"},{"key":"1220_CR10","first-page":"313","volume-title":"Pharmacovigilance","author":"M Harrison-Woolrych","year":"2006","unstructured":"Harrison-Woolrych M, Coulter DM (2006) PEM in New Zealand. In: Mann R, Andrews EB (eds) Pharmacovigilance, 2nd edn. John Wiley and Sons, Chichester, pp 313\u2013328","edition":"2"},{"issue":"1283","key":"1220_CR11","first-page":"76","volume":"121","author":"DL Kunac","year":"2008","unstructured":"Kunac DL, Harrison-Woolrych M, Tatley MV (2008) Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use. N Z Med J 121(1283):76\u201389","journal-title":"N Z Med J"},{"issue":"12","key":"1220_CR12","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jama.1975.03260250028021","volume":"234","author":"FE Karch","year":"1975","unstructured":"Karch FE, Lasagna L (1975) Adverse drug reactions. A critical review. JAMA 234(12):1236\u20131241","journal-title":"JAMA"},{"key":"1220_CR13","first-page":"277","volume-title":"Pharmacovigilance","author":"KVPE Grootheest Van","year":"2007","unstructured":"Van Grootheest KVPE (2007) Pharmacovigilance in the Netherlands. In: Mann R, Andrews EB (eds) Pharmacovigilance, Secondth edn. John Wiley and Sons, Chichester, pp 277\u2013285","edition":"Second"},{"key":"1220_CR14","doi-asserted-by":"crossref","unstructured":"Harmark L, van Puijenbroek E, Straus S, van Grootheest K. Intensive monitoring of pregabalin: results from an observational, Web-based, prospective cohort study in the Netherlands using patients as a source of information. Drug Saf 34(3):221\u2013231.","DOI":"10.2165\/11585030-000000000-00000"},{"issue":"10","key":"1220_CR15","first-page":"903","volume":"32","author":"RA Cox","year":"2009","unstructured":"Cox RA, Varenicline C (2009) Evaluation of the utility of spontaneous consumer reports of suspected adverse effects on internet sites. Drug Saf 32(10):903\u2013904","journal-title":"Drug Saf"},{"issue":"10","key":"1220_CR16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1093\/qjmed\/hcg129","volume":"96","author":"S Kamath","year":"2003","unstructured":"Kamath S, Lip GYH (2003) Fibrinogen: biochemistry, epidemiology and determinants. Q J Med 96(10):711\u2013729","journal-title":"Q J Med"},{"issue":"9","key":"1220_CR17","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/0895-4356(90)90075-Z","volume":"43","author":"AJ Lee","year":"1990","unstructured":"Lee AJ, Smith WCS, Lowe GDO, Tunstall-Pedoe H (1990) Plasma fibrinogen and coronary risk factors: The Scottish Heart Health Study. J Clin Epidemiol 43(9):913\u2013919","journal-title":"J Clin Epidemiol"},{"issue":"12","key":"1220_CR18","first-page":"1318","volume":"116","author":"G Miller","year":"1992","unstructured":"Miller G (1992) Hemostasis and cardiovascular risk. The British and European experience. Arch Pathol Lab Med 116(12):1318\u20131321","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"1220_CR19","first-page":"986","volume":"31","author":"IJ Meade TW","year":"1987","unstructured":"Meade TW IJ, Stirling Y (1987) Effects of changes in smoking and other characteristics on clotting factors and the risk of ischaemic heart disease. Lancet 31(2):986\u2013988","journal-title":"Lancet"},{"issue":"2","key":"1220_CR20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0021-9150(95)05716-1","volume":"121","author":"MPM Maat de","year":"1996","unstructured":"de Maat MPM, Pietersma A, Kofflard M, Sluiter W, Kluft C (1996) Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis 121(2):185\u2013191","journal-title":"Atherosclerosis"},{"issue":"4","key":"1220_CR21","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S1047-2797(00)00226-X","volume":"11","author":"M Tuut","year":"2001","unstructured":"Tuut M, Hense H-W (2001) Smoking, other risk factors and fibrinogen levels: evidence of effect modification. Ann Epidemiol 11(4):232\u2013238","journal-title":"Ann Epidemiol"},{"issue":"17","key":"1220_CR22","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1093\/eurheartj\/ehi183","volume":"26","author":"SG Wannamethee","year":"2005","unstructured":"Wannamethee SG, Lowe GDO, Shaper AG, Rumley A, Lennon L, Whincup PH (2005) Associations between cigarette smoking, pipe\/cigar smoking, and smoking cessation, and haemostatic and inflammatory markers for cardiovascular disease. Eur Heart J 26(17):1765\u20131773","journal-title":"Eur Heart J"},{"issue":"5","key":"1220_CR23","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1378\/chest.06-2179","volume":"131","author":"DG Yanbaeva","year":"2007","unstructured":"Yanbaeva DG, Dentener MA, Creutzberg EC, Wesseling G, Wouters EFM (2007) Systemic effects of smoking. Chest 131(5):1557\u20131566","journal-title":"Chest"},{"issue":"1","key":"1220_CR24","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1902\/jop.2004.75.1.16","volume":"75","author":"T Dietrich","year":"2004","unstructured":"Dietrich T, Bernimoulin J-P, Glynn RJ (2004) The effect of cigarette smoking on gingival bleeding. J Periodontol 75(1):16\u201322","journal-title":"J Periodontol"},{"issue":"5","key":"1220_CR25","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1034\/j.1600-051X.2003.20039.x","volume":"30","author":"P Nair","year":"2003","unstructured":"Nair P, Sutherland G, Palmer RM, Wilson RF, Scott DA (2003) Gingival bleeding on probing increases after quitting smoking. J Clin Periodontol 30(5):435\u2013437","journal-title":"J Clin Periodontol"},{"issue":"S1","key":"1220_CR26","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1002\/hup.917","volume":"23","author":"RJ Flanagan","year":"2008","unstructured":"Flanagan RJ, Dunk L (2008) Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol Clin Exp 23(S1):S27\u2013S41","journal-title":"Hum Psychopharmacol Clin Exp"},{"issue":"1","key":"1220_CR27","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/clpt.2010.240","volume":"89","author":"BM Verdel","year":"2011","unstructured":"Verdel BM, Souverein PC, Meenks SD, Heerdink ER, Leufkens HGM, Egberts TCG (2011) Use of serotonergic drugs and the risk of bleeding. Clin Pharmacol Ther 89(1):89\u201396","journal-title":"Clin Pharmacol Ther"},{"key":"1220_CR28","doi-asserted-by":"crossref","unstructured":"Andrade C, Sandarsh S, Chethan KB, Nagesh KS (2010) Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. Physicians Postgraduate Press, Memphis","DOI":"10.4088\/JCP.09r05786blu"},{"issue":"4","key":"1220_CR29","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10557-010-6246-8","volume":"24","author":"J McNeil","year":"2010","unstructured":"McNeil J, Piccenna L, Ioannides-Demos L (2010) Smoking cessation\u2014recent advances. Cardiovasc Drugs Ther 24(4):359\u2013367","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"1220_CR30","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.neuint.2010.10.015","volume":"58","author":"H Rollema","year":"2011","unstructured":"Rollema H, Wilson GG, Lee TC, Folgering JHA, Flik G (2011) Effect of co-administration of varenicline and antidepressants on extracellular monoamine concentrations in rat prefrontal cortex. Neurochem Int 58(1):78\u201384","journal-title":"Neurochem Int"},{"issue":"4","key":"1220_CR31","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1161\/ATVBAHA.110.218297","volume":"31","author":"A Schedel","year":"2011","unstructured":"Schedel A, Thornton S, Schloss P, Kluter H, Bugert P (2011) Human platelets express functional {alpha}7-nicotinic acetylcholine receptors. Arterioscler Thromb Vasc Biol 31(4):928\u2013934","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-012-1220-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-012-1220-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-012-1220-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,23]],"date-time":"2019-06-23T08:33:57Z","timestamp":1561278837000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-012-1220-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,8]]},"references-count":31,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1007\/s00228-012-1220-y","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,8]]}}}